Improving treatment for obese women with early stage cancer of the uterus: Rationale and design of the levonorgestrel intrauterine device±Metformin±weight loss in endometrial cancer (feMME) trial

Contemporary Clinical Trials

Volumn 39, Issue 1, 2014, Pages 14-21

  Hawkes, A L ^a   Quinn, M ^b   Gebski, V ^c   Armes, J ^d   Brennan, D ^e   Janda, M ^a   Obermair, A ^a,e  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b ROYAL WOMEN'S HOSPITAL   (Australia)

^c NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL   (Australia)

^d MATER ADULT HOSPITAL   (Australia)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Endometrial cancer; Levonorgestrel intrauterine device; Metformin; Physical activity; Progestin Progesterone; Weight loss

Indexed keywords

LEVONORGESTREL; METFORMIN; GESTAGEN; GLUCOSE; PROGESTERONE;

ABDOMINAL PAIN; ADULT; AMENORRHEA; ARTICLE; CLINICAL EFFECTIVENESS; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; EARLY CANCER; ENDOMETRIUM CARCINOMA; FEMALE; HEALTH CARE UTILIZATION; HUMAN; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MEDICAL DEVICE COMPLICATION; METRORRHAGIA; MULTICENTER STUDY; NAUSEA; OBESITY; OPEN STUDY; OVARY CYST; PELVIC PAIN; PHASE 2 CLINICAL TRIAL; PHYSICAL ACTIVITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SPOTTING; TASTE DISORDER; TREATMENT RESPONSE; UTERUS BLEEDING; VAGINA BLEEDING; VOMITING; WEIGHT REDUCTION; BODY HEIGHT; BODY WEIGHT; CANCER STAGING; ENDOMETRIUM CANCER; GLUCOSE BLOOD LEVEL; HIP CIRCUMFERENCE; HUMAN TISSUE; HYSTEROSCOPY; PROSPECTIVE STUDY; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WEIGHT LOSS PROGRAM;

EID: 84904462965     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2014.06.014     Document Type: Article

References (58)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Fader A.N., Arriba L.N., Frasure H.E., von Gruenigen V.E. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 2009, 114:121-127.
3. Leitao M.M., Han G., Lee L.X., Abu-Rustum N.R., Brown C.L., Chi D.S., et al. Complex atypical hyperplasia of the uterus: characteristics and prediction of underlying carcinoma risk. Am J Obstet Gynecol 2010, 203:349e1-349e6.
4. Lacey J.V., Sherman M.E., Rush B.B., Ronnett B.M., Ioffe O.B., Duggan M.A., et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol 2010, 28:788-792.
5. Bovicelli A., D'Andrilli G., Giordano A., De Iaco P. Conservative treatment of early endometrial cancer. J Cell Physiol 2013, 228:1154-1158.
6. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004, 4:579-591.
7. Kaaks R., Lukanova A., Kurzer M.S. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002, 11:1531-1543.
8. von Gruenigen V., Tian C., Frasure H., Waggoner S., Keys H., Barakat R.R. Treatment effects, toxicity, disease recurrence and survival in obese women with early endometrial carcinoma: a Gynecologic Oncology Group study. Cancer 2006, 107:2786-2791.
9. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003, 348:1625-1638.
10. Creasman W.T., Odicino F., Maisonneuve P., Quinn M.A., Beller U., Benedet J.L., et al. Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006, 95(Suppl. 1):S105-S143.
11. Tangjitgamol S., Anderson B.O., See H.T., Lertbutsayanukul C., Sirisabya N., Manchana T., et al. Management of endometrial cancer in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009, 10:1119-1127.
12. Obermair A., Nascimento M., Neesham D., Nicklin J.L., Oehler M.K., Otton G., et al. Improved surgical safety after laparoscopic compared to open surgery for apparent early stage endometrial cancer: results from a randomised controlled trial. Eur J Cancer 2012, 48:1147-1153.
13. Kondalsamy-Chennakesavan S., Nascimento M., Neesham D., Nicklin J.L., Oehler M.K., Otton G., et al. Risk factors to predict the incidence of surgical adverse events following open or laparoscopic surgery for apparent early stage endometrial cancer: results from a randomised controlled trial. Eur J Cancer 2012, 48:2155-2162.
14. Zullo F., Falbo A., Palomba S. Safety of laparoscopy vs laparotomy in the surgical staging of endometrial cancer: a systematic review and metaanalysis of randomized controlled trials. Am J Obstet Gynecol 2012, 207:94-100.
15. Gadducci A., Spirito N., Baroni E., Tana R., Genazzani A.R. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option. Gynecol Endocrinol 2009, 25:683-691.
16. Gunderson C.C., Fader A.N., Carson K.A., Bristow R.E. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 2012, 125:477-482.
17. Wang C.B., Wang C.J., Huang H.J., Hsueh S., Chou H.H., Soong Y.K., et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. Cancer 2002, 94:2192-2198.
18. Wirtberg I., Moller A., Hogstrom L., Tronstad S.E., Lalos A. Life 20years after unsuccessful infertility treatment. Hum Reprod 2007, 22:598-604.
19. Bost F., Sahra I.B., Le Marchand-Brustel Y., Tanti J.F. Metformin and cancer therapy. Curr Opin Oncol 2012, 24:103-108.
20. Gallagher E.J., LeRoith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann N Y Acad Sci 2011, 1243:54-68.
21. Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) 2010, 3:1060-1065.
22. Schuler K.M., Rambally B.S., DiFurio M.J., Gehrig P.A., Bae-Jump V.L. A preoperative window study of metformin for the treatment of endometrial cancer. J Clin Oncol 2013, 31. [Suppl.; abstr 5519].
23. Soliman P.T., Broaddus R., Westin S.N., Iglesias D.A., Burzawa J.K., Zhang Q., et al. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study. J Clin Oncol 2014, 32:5s. [Suppl.; abstr 5510].
24. von Gruenigen V.E., Courneya K.S., Gibbons H.E., Kavanagh M.B., Waggoner S.E., Lerner E. Feasibility and effectiveness of a lifestyle intervention program in obese endometrial cancer patients: a randomized trial. Gynecol Oncol 2008, 109:19-26.
25. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
26. Appel L.J., Champagne C.M., Harsha D.W., Cooper L.S., Obarzanek E., Elmer P.J., et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003, 289:2083-2093.
27. von Gruenigen V., Frasure H., Kavanagh M.B., Janata J., Waggoner S., Rose P., et al. Survivors of uterine cancer empowered by exercise and healthy diet (SUCCEED): a randomized controlled trial. Gynecol Oncol 2012, 125:699-704.
28. Nicklin J., Janda M., Gebski V., Jobling T., Land R., Manolitsas T., et al. The utility of serum CA-125 in predicting extra-uterine disease in apparent early-stage endometrial cancer. Int J Cancer 2012, 131(4):885-890.
29. Nicklin J., Janda M., Gebski V., Jobling T., Land R., Manolitsas T., et al. The utility of serum CA-125 in predicting extra-uterine disease in apparent early-stage endometrial cancer. Int J Cancer 2012, 131:885-890.
30. Charlson M.E., Charlson R.E., Peterson J.C., Marinopoulos S.S., Briggs W.M., Hollenberg J.P. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 2008, 61:1234-1240.
31. Bolen S., Feldman L., Vassy J., Wilson L., Yeh H.C., Marinopoulos S., et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007, 147:386-399.
32. Jebb S.A., Ahern A.L., Olson A.D., Aston L.M., Holzapfel C., Stoll J., et al. Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial. Lancet 2011, 378:1485-1492.
33. ICH Expert Working Group Guideline for Good Clinical Practice 1996, [Accessed 8 December 2011].
34. EORTC Common toxicity Criteria (CTC) 2011, [Accessed 8 December 2011].
35. Cella D.F. Manual of the functional assessment of chronic illness therapy (FACIT Scales) - Version 4 1997, Center on Outcomes Research and Education (CORE), Evanston Northwestern Healthcare & Northwestern University, Evanston, IL.
36. Cella D.F., Tulsky D.S., Gray G., Sarafian B., Linn E., Bonomi A., et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993, 11:570-579.
37. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370.
38. Ritter P.L., Stewart A.L., Kaymaz H., Sobel D.S., Block D.A., Lorig K.R. Self-reports of health care utilization compared to provider records. J Clin Epidemiol 2001, 54:136-141.
39. Barber M.D., Chen Z., Lukacz E., Markland A., Wai C., Brubaker L., et al. Further validation of the short form versions of the Pelvic Floor Distress Inventory (PFDI) and Pelvic Floor Impact Questionnaire (PFIQ). Neurourol Urodyn 2011, 30:541-546.
40. AIHW The Active Australia Survey: a Guide and Manual for Implementation, Analysis and Reporting 2003, AIHW, Canberra.
41. Snaith R.P. The Hospital Anxiety And Depression Scale. Health Qual Life Outcomes 2003, 1:29.
42. Cella D. FACIT Manual. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System 1997, Evanston Northwestern Healthcare and Northwestern University. R.a.E.C. Center on Outcomes (Ed.).
43. Lorig K., Stewart A., Ritter P., Gonzalez V., Laurent D., Lynch J. Outcome Measures for Health Education and other Health Care Interventions 1996, Sage Publications, Thousand Oaks CA.
44. Barber M.D., Walters M.D., Bump R.C. Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7). Am J Obstet Gynecol 2005, 193:103-113.
45. Giles G., Ireland P. Dietary Questionnaire for Epidemiologic Studies (Version 2) 1996, The Cancer Council Victoria, Melbourne.
46. Marcus B.H., Selby V.C., Niaura R.S., Rossi J.S. Self-efficacy and the stages of exercise behavior change. Res Q Exerc Sport 1992, 63:60-66.
47. Sallis J.F., Grossman R.M., Pinski R.B., Patterson T.L., Nader P.R. The development of scales to measure social support for diet and exercise behaviors. Prev Med 1987, 16:825-836.
48. Baker J., Obermair A., Gebski V., Janda M. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol 2012, 125:263-270.
49. Flemming R., Sathiyathasan S., Jackson A. Endometrioid adenocarcinoma after insertion of a levonorgestrel-releasing intrauterine system. J Minim Invasive Gynecol 2008, 15:771-773.
50. Kothari R., Seamon L., Cohn D., Fowler J., O'Malley D.M. Stage IV endometrial cancer after failed conservative management: a case report. Gynecol Oncol 2008, 111:579-582.
51. Schmandt R.E., Iglesias D.A., Co N.N., Lu K.H. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol 2011, 205:518-525.
52. Dowling R.J., Zakikhani M., Fantus I.G., Pollak M., Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007, 67:10804-10812.
53. Zakikhani M., Dowling R., Fantus I.G., Sonenberg N., Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006, 66:10269-10273.
54. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
55. Shen Z.Q., Zhu H.T., Lin J.F. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. Obstet Gynecol 2008, 112:465-467.
56. Zhang Z., Dong L., Sui L., Yang Y., Liu X., Yu Y., et al. Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression. Int J Gynecol Cancer 2011, 21:213-221.
57. Xie Y., Wang Y.L., Yu L., Hu Q., Ji L., Zhang Y., et al. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol 2011, 126:113-120.
58. Bandura A. Social Foundations of thought and action: A social cognitive theory 1986, Prentice Hall International Inc., Englewood Cliffs, NJ.